Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug-Reference-Cited by-同舟云学术

Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug

Published:2004-04 Issue:4 Volume:78 Page:767-776
ISSN:0014-4835
Container-title:Experimental Eye Research
language:en
Short-container-title:Experimental Eye Research

Author:

Takagi Yasutaka,Nakajima Tadashi,Shimazaki Atsushi,Kageyama Masaaki,Matsugi Takeshi,Matsumura Yasushi,Gabelt B'Ann T.,Kaufman Paul L.,Hara Hideaki

Publisher

Elsevier BV

Subject

Cellular and Molecular Neuroscience,Sensory Systems,Ophthalmology

Reference37 articles.

1. Cloning and expression of a cDNA for the human prostanoid FP receptor;Abramovitz;J. Biol. Chem.,1994

2. Comparative phase III clinical trial of latanoprost and timolol in patients with elevated intraocular pressure;Alm;Adv. Prostaglandin Thromboxane Leukot. Res.,1995

3. Phase III latanoprost studies in Scandinavia, the United Kingdom and the United States;Alm;Surv. Ophthalmol.,2000

4. Simultaneous measurements of changing intraocular pressure and outflow facility in the vervet monkey by constant pressure infusion;Bárány;Invest. Ophthalmol.,1964

5. Pressure dependence of uveoscleral outflow;Becker;J. Glaucoma,2002

Cited by 139 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tafluprost promotes axon regeneration after optic nerve crush via Zn2+-mTOR pathway;Neuropharmacology;2024-01

2. Efficacy of preserved Tafluprost 0.0015% in lowering intraocular pressure;Indian Journal of Ophthalmology;2023-11-20

3. Three Major Causes of Metabolic Retinal Degenerations and Three Ways to Avoid Them;International Journal of Molecular Sciences;2023-05-13

4. Ligand-induced activation and G protein coupling of prostaglandin F2α receptor;Nature Communications;2023-05-09

5. FP and EP2 prostanoid receptor agonist drugs and aqueous humor outflow devices for treating ocular hypertension and glaucoma;Experimental Eye Research;2023-04